Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Sanofi posts Q3 revenue beat
Sanofi posts Q3 revenue beat as Dupixent sales jump
Sanofi (NASDAQ:SNY) shares gained on Friday after the French pharma giant exceeded analysts' estimates with its Q3 thanks mainly to earlier-than-anticipated vaccine sales and a 22% YoY rise in sales from its asthma therapy Dupixent.
Sanofi Earns $5B Q3 Core Profit On Strong Dupixent And Vaccine Sales, Raises 2024 Forecast
On Friday, Sanofi SA (NASDAQ:SNY) reported a third-quarter business operating income of 4.61 billion euros ($4.99 billion), up 14.4% year-over-year and 19.9% in constant currency. The company reported third-quarter sales of 13.
Sanofi Beats Q3 Forecasts Fueled by 381% Growth in Beyfortus Sales
The French drugmaker’s newly launched respiratory syncytial virus antibody Beyfortus far exceeded analyst expectations, bringing in almost $700 million in the third quarter. Leerink Partners analyst David Risinger in a Friday note to investors said Sanofi expects Q4 Beyfortus sales similar to Q3.
Sanofi profit growth beats market view on early start of vaccine sales
French drug maker Sanofi on Friday posted stronger earnings growth than analysts had expected in the third quarter, helped by earlier-than-anticipated sales of seasonal vaccines.
Sanofi SA (SNY) Q3 2024 Earnings Call Highlights: Strong Sales Growth and Strategic Advances
Sanofi SA (SNY) reports a robust 16% sales increase, driven by Dupixent and vaccines, while navigating market challenges and strategic divestments.
Dow's stock rises as Q3 sales beat estimates
Dow’s (NYSE:DOW) stock rose 1.5% on Thursday morning after the chemical maker reported third-quarter results. Adjusted earnings were $0.47 a share, in line with the consensus estimate. Net sales rose 1% from a year earlier to $10.
2d
Sanofi (SNY) Q3 2024 Earnings Call Transcript
Sanofi (NASDAQ: SNY) Q3 2024 Earnings Call Oct 25, 2024, 8:00 a.m. ET Welcome to the Q3 2024 conference call for investors ...
3d
on MSN
Sanofi CEO Paul Hudson on Q3 results: The modernization effort is starting to pay off
Sanofi CEO Paul Hudson joins 'Squawk Box' to discuss the company's quarterly earnings results, drug pipeline outlook, the ...
The Pharma Letter
3d
Sanofi outpaces expectations in third quarter 2024
Sanofi reported Q3 2024 sales growth of 15.7%, reaching 13.4 billion euros ($14.2 billion), with EPS up 12.2% to 2.86 euros.
Business Times
2d
Sanofi profit lifted by early vaccine sales, Dupixent growth
Sanofi
profit rose on demand for seasonal vaccines and further growth in its blockbuster skin and asthma therapy Dupixent.
1d
Analysts Are Neutral on Top Healthcare Stocks: Sanofi (SNYNF), Siegfried Holding AG (SGFEF)
RBC Capital analyst Charles Weston maintained a Hold rating on Siegfried Holding AG on October 25 and set a price target of CHF1125.00. The company’s shares closed last Thursday at $965.00, equals to ...
7d
on MSN
CD&R is said to near Sanofi OTC deal after commitments to France
Clayton Dubilier & Rice is set to buy Sanofi's consumer health unit with social commitments, including job creation ...
7d
on MSN
Sanofi in exclusive talks with CD&R over sale of $17 billion Opella
PARIS (Reuters) -French drugmaker Sanofi said on Monday it had entered exclusive talks to sell a 50% controlling stake in its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback